Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations.

IF 2.8 4区医学 Q2 CLINICAL NEUROLOGY

Revue neurologique Pub Date : 2024-07-04 DOI:10.1016/j.neurol.2024.06.003

Romain Deschamps, Caroline Papeix, Xavier Ayrignac, Bertrand Bourre, Jonathan Ciron, Mikael Cohen, Nicolas Collongues, Kumaran Deiva, Françoise Durand Dubief, David-Axel Laplaud, Elisabeth Maillart, Laure Michel, Julie Pique, Aurélie Ruet, Eric Thouvenot, Hélène Zéphir, Romain Marignier, Bertrand Audoin

引用次数: 0

查看原文本刊更多论文

在法国倡导将利妥昔单抗作为 NMOSD-AQP4 患者的一线治疗：成本和疗效考虑因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revue neurologique 医学-临床神经学

CiteScore

4.80

自引率

0.00%

发文量

598

审稿时长

55 days

期刊介绍： The first issue of the Revue Neurologique, featuring an original article by Jean-Martin Charcot, was published on February 28th, 1893. Six years later, the French Society of Neurology (SFN) adopted this journal as its official publication in the year of its foundation, 1899. The Revue Neurologique was published throughout the 20th century without interruption and is indexed in all international databases (including Current Contents, Pubmed, Scopus). Ten annual issues provide original peer-reviewed clinical and research articles, and review articles giving up-to-date insights in all areas of neurology. The Revue Neurologique also publishes guidelines and recommendations. The Revue Neurologique publishes original articles, brief reports, general reviews, editorials, and letters to the editor as well as correspondence concerning articles previously published in the journal in the correspondence column.

文献相关原料

公司名称	产品信息	采购帮参考价格